Capital Performance Advisors’s Eli Lilly LLY Stock Holding History

Capital Performance Advisors’s Portfolio LLY Stock Details LLY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.34M	Buy	3,632 +434	+14%	+$440K	0.22%	55
2025 Q4	$3.44M	Buy	3,198 +452	+16%	+$432K	0.24%	53
2025 Q3	$2.1M	Buy	2,746 +494	+22%	+$368K	0.35%	42
2025 Q2	$1.76M	Sell	2,252 -437	-16%	-$340K	0.34%	46
2025 Q1	$2.22M	Buy	2,689 +2,100	+357%	+$1.75M	0.49%	35
2024 Q4	$455K	Sell	589 -171	-23%	-$142K	0.15%	62
2024 Q3	$673K	Buy	760 +300	+65%	+$270K	0.2%	42
2024 Q2	$417K	Buy	460 +36	+8%	+$28.8K	0.16%	53
2024 Q1	$330K	Buy	424 +51	+14%	+$36.3K	0.13%	56
2023 Q4	$217K	Buy	+373	New	+$218K	0.09%	66

Other funds holding LLY

Lilly Endowment Indiananapolis, Indiana $108B AUM 53.87% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital Performance Advisors's LLY Position: Q1 2026 in Review

Capital Performance Advisors increased its Eli Lilly (LLY) stake by 14% in Q1 2026, buying an estimated $440K and bringing the position to 3,632 shares worth $3.34M. The position accounts for 0.22% of the portfolio, ranked #55.

Capital Performance Advisors first reported a position in LLY in Q4 2023 and has held it in 10 quarters since. The position peaked at $3.44M in Q4 2025. 4,354 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

Capital Performance Advisors held 3,632 shares of Eli Lilly worth $3.34M as of Q1 2026.
Capital Performance Advisors bought 434 Eli Lilly shares in Q1 2026, an estimated $440K.
Eli Lilly made up 0.22% of Capital Performance Advisors's portfolio in Q1 2026, its #55 holding.
Capital Performance Advisors first reported a position in Eli Lilly in Q4 2023 and has held it in 10 quarters since.
Capital Performance Advisors's Eli Lilly position peaked at $3.44M in Q4 2025.
4,354 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Capital Performance Advisors's 13F filing for Q1 2026, filed 7 May 2026.